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Regulation of nuclear import is fundamental to
eukaryotic biology. The majority of nuclear import
pathways are mediated by importin-cargo inter-
actions. Yet not all nuclear proteins interact with im-
portins, necessitating the identification of a general
importin-independent nuclear import pathway.
Here, we identify a code that determines importin-
independent nuclear import of ankyrin repeats
(ARs), a structural motif found in over 250 human pro-
teins with diverse functions. AR-containing proteins
(ARPs) with a hydrophobic residue at the 13th posi-
tion of two consecutive ARs bind RanGDP efficiently,
and consequently enter the nucleus. This code,
experimentally tested in 17 ARPs, predicts the nu-
clear-cytoplasmic localization of over 150 annotated
human ARPs with high accuracy and is acquired by
the most common familial melanoma-associated
CDKN2A mutation, leading to nuclear accumulation
of mutant p16ink4a. The RaDAR (RanGDP/AR)
pathway represents a general importin-independent
nuclear import pathway and is frequently used by
AR-containing transcriptional regulators, especially
those regulating NF-kB/p53.INTRODUCTION
Nuclear transport of macromolecules is a fundamental biological
process lying at the heart of eukaryotic gene expression and cell
fate determination. The nuclear import of large molecules
(>40 kDa) and/or the accumulation of small molecules against
a concentration gradient requires facilitated transport (Adams
andWente, 2013; Mohr et al., 2009). Most established facilitated
transport mechanisms are mediated by nuclear transport pro-
teins called karyopherin-bs (Kap-bs, also known as importins
and exportins in humans) (Go¨rlich and Kutay, 1999; Stewart,
2007; Weis, 2003). Eleven of 19 known Kap-bs are involved in
nuclear import (Chook and Su¨el, 2011). The best-characterized
nuclear import process is mediated by importin-cargo interac-1130 Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc.tions in which importins (importins 2-5, 7-9, 11-13 and exportin
4) interact with nuclear localization signal (NLS)-containing car-
gos. The resulting importin-cargo complex interacts with phenyl-
alanine-glycine repeat containing nucleoporins (FG-Nups) to
pass through the nuclear pore complex (NPC). A prerequisite
of this important system is the asymmetric distribution of
RanGDP and RanGTP between the cytoplasm and nucleus.
The cytoplasm has relatively high RanGDP levels, gained
through the activity of the cytoplasmic RanGTPase-activating
protein (RanGAP). In the nucleus, RanGDP is converted to
RanGTP by nuclear Ran guanine nucleotide exchange factor
(RCC1). The high nuclear concentration of RanGTP enables it
to compete with the cargos to bind importin, thus enabling
release of NLS-containing cargos into the nucleoplasm.
The formation of the RanGTP/importin-b complex accom-
panies the termination of nuclear import, followed by recycling
of importins and RanGTP to the cytoplasm (Kutay et al., 1997;
Stewart, 2007). RanGTP is also exported to the cytoplasm by
coupling to the exportin-mediated nuclear export pathway.
Despite of the continuous nuclear export of RanGTP, >90% of
Ran resides in the nucleus, which cannot be achieved by passive
diffusion (Kim and Elbaum, 2013). This has led to the identifica-
tion of nuclear transport factor 2 (NTF2) as an important nuclear
import facilitator of RanGDP (Ribbeck et al., 1998). NTF2-medi-
ated nuclear import of RanGDP is a continuous and extremely
efficient event. The low-energy GDP form of Ran has historically
been viewed as the ‘‘off’’ state because it does not directly
participate in various identified nuclear import/export pathways
(Cook et al., 2007), and the function of RanGDP in nuclear-cyto-
plasmic transport has not yet been identified. Interestingly, the
actin-associated protein CapG is reported to bind NTF2 to
achieve nuclear entry with the assistance of Ran and Nup62
(Van Impe et al., 2008). Thus, a key question is whether the
extremely efficient NTF2-RanGDP import pathway can be used
by other cargos as a facilitated nuclear import pathway.
While the best-characterized nuclear import pathways are
mediated by importin-NLS-containing cargo interactions, many
nuclear proteins do not contain a currently identifiable NLS
(Chook and Su¨el, 2011). A bioinformatics study shows that
only 60% of the nuclear proteome contain identifiable NLS
sequences (Brameier et al., 2007). Additionally, the importin-
independent pathways that have been identified to date
tend to be cargo specific. For example, nuclear import of
Hsp70s-ATP is mediated by Hikeshi (Kose et al., 2012); CapG is
mediated by NTF2/Ran/Nup62 (Van Impe et al., 2008); b-catenin
is mediated by direct nucleoporin binding (Fagotto et al., 1998);
and RanGDP is mediated by NTF2 (Ribbeck et al., 1998).
Collectively, these observations imply the presence of at least
one general nuclear import system that is independent of
importins.
Intriguingly, a number of ankyrin repeat domains (ARDs), such
as those from IkBa, ASPP2, and GABPb, have been reported to
enter the nucleus via an unknown mechanism independent of a
NLS (Sachdev et al., 1998). The ankyrin repeat (AR) is one of the
most common protein structural motifs. To date, >265 human
proteins are annotated as AR-containing proteins (ARPs) in the
SMART database. ARs are evolutionarily conserved protein
modules, of33 residues and an L-shaped structure, composed
of two antiparallel a helices of 8–10 residues preceded by a
b-hairpin. The Ankyrin family is one of the most representative
ARP families. Its members (AnkyrinR/B/G) are adaptor proteins
that mediate the attachment of integral membrane proteins to
the spectrin-actin-based membrane cytoskeleton (Bennett and
Baines, 2001), thus ARPs are often thought of as scaffold pro-
teins. However, ARPs also play pivotal roles in the development
andmaintenance of tissue homeostasis by functioning at the cell
membrane, cytoplasm, and nucleus. Some ARPs interact with
their ligands with nanomolar affinity and high specificity, forming
the basis of synthetic AR-based ‘‘alternative antibodies’’ (such
as DARPin), which efficiently target binding partners (Dreier
et al., 2013).
Mutations in the ARDs of ARPs have been associated with
various human diseases. For example, mutations in AnkyrinR
and AnkyrinB correlate with hereditary spherocytosis (Eber
et al., 1996) and cardiac arrhythmia (Mohler et al., 2003), respec-
tively. Recent studies also suggest their importance in tumori-
genesis. The ARD of Notch is mutated in human lung and head
and neck cancers (Agrawal et al., 2011). The most frequent
p16ink4a (p16, encoded by CDKN2A) mutation in human familial
melanomas is methionine to isoleucine at residue 53 (M53I),
resulting in the nuclear enrichment of p16 (Ghiorzo et al.,
2004). It remains unknown why a point mutation in p16 can facil-
itate its nuclear localization. The importance of ARP localization
in tumorigenesis is further supported by recent discoveries of
how the ASPP protein family functions. The ASPP family was
originally identified as transcriptional regulators of p53 (Sam-
uels-Lev et al., 2001) and RelA/p65 (Yang et al., 1999), and con-
sists of three members (ASPP1, ASPP2, and iASPP) that shuttle
between the cytoplasm and nucleus. ASPP1 binds YAP and acts
as an oncogene in the cytoplasm (Vigneron et al., 2010) but acts
as a tumor suppressor in the nucleus by enhancing p53-medi-
ated apoptosis (Aylon et al., 2010). In the cytoplasm, ASPP2
binds Ras and inhibits autophagy (Wang et al., 2013). ASPP2’s
N terminus also binds Par3 to maintain the integrity of apical
polarity and tight junctions (Sottocornola et al., 2010). In the
nucleus, ASPP2 is a transcriptional activator of the p53 family
and a tumor suppressor that co-operates with p53 to suppress
tumor growth in vivo (Vives et al., 2006). Similarly, iASPP is a
nuclear protein in proliferating basal epithelial cells but cyto-
plasmic in differentiated epithelial cells in human cervical or
skin epithelia in vivo (Notari et al., 2011). During G2/M transition,cyclin B/CDK1 phosphorylates Ser84 and Ser113 of iASPP, re-
sulting in its nuclear entry and enhanced inhibition of p53 (Lu
et al., 2013). Deregulation of Ser84 and Ser113 phosphorylation
is a key reason for the loss of p53’s tumor suppressive function in
human melanoma. These findings demonstrate the importance
of the cellular localizations of ASPP in regulating their functions.
However, little is known about the mechanisms mediating their
nuclear entry, except for observations that, like IkBa, ASPP2’s
ARD and the ARD and SH3-containing C terminus of iASPP
can enter the nucleus without an identifiable NLS in vitro (Sach-
dev et al., 1998; Slee et al., 2004). Here, we reveal that a group
of ARDs possess a protein code, consisting of hydrophobic res-
idues at the 13th position of the consensus AR sequences in two
consecutive ARs to form a 3D-bindingmotif for RanGDPbinding,
which mediates nuclear entry. Thus, the RanGDP/AR (RaDAR)
complex-mediated nuclear import system represents a general
importin-independent nuclear import pathway.
RESULTS
ARs of ASPP Enter the Nucleus via an Importin-
Independent Pathway
Increased cytoplasmic GTP concentration inhibits importin-
dependent nuclear import because elevated RanGTP in the
cytoplasm prevents NLS-containing proteins from interacting
with importins (Melchior et al., 1993). Thus, the ability of cyto-
plasmic GTP or GTPgS (a nonhydrolyzable GTP analog that
cannot supply energy) to influence nuclear entry in a digitonin-
permeabilized in vitro nuclear import assaymay indicate whether
a protein employs the importin-dependent or an independent
pathway to enter the nucleus.
Recombinant GST-tagged ARs from iASPP and ASPP2,
iASPP-ARs-GST, and ASPP2-ARs-GST (Figure S1A available
online) were purified and their ability to enter the nucleus
compared with GST-tagged NLS-GFP (NLS-GFP-GST), which
contains the SV40 NLS sequence (Figure 1A). FITC-labeled
ASPP-ARs-GST and NLS-GFP-GST entered the nucleus effi-
ciently when loaded onto digitonin-treated cells. Under the
same conditions, FITC-labeled GST did not enter the nucleus
(Figure S1B). The presence of GTP or GTPgS abrogated NLS-
GFP-GST’s nuclear entry; in contrast they enhanced the nuclear
entry of ASPP-ARs-GST (Figure 1A). To our knowledge, RanGDP
is the only protein whose nuclear import can be enhanced by the
addition of GTP (Ribbeck et al., 1998), as confirmed here
(Figure 1A).
The ability of ASPP-ARs-GST to interact with key components
of the well-defined classical nuclear import pathway was then
further investigated. As expected, NLS-GFP-GST pulled down
importin-a, whereas GST-RanGDP pulled down Ran-binding
domain-containing Nup358 and Nup153 (Figures 1B and S1C).
Under the same conditions, ASPP-ARs-GST failed to complex
with FG-Nups Nup358, Nup214, Nup98, or Nup62, which span
the NPC. This may be due to the fact that interactions between
transport complexes and FG-repeats are transient with a low
affinity. However, FG-Nup Nup153, which resides at the nuclear
ring of NPC, interacted with ASPP-ARs-GST, NLS-GFP-GST,
and GST-RanGDP. ASPP-ARs-GST pulled down Ran as well
as NTF2 (Figure 1B).Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc. 1131
Figure 1. Nuclear Import of ASPP-ARs via an Importin-Independent Pathway
(A) Digitonin-treated semipermeable H1299 cells were incubated with FITC-labeled substrates (purified ASPP-ARs-GST or NLS-GFP-GST) in the presence of
10 mg/ml H1299 cytosol and an energy-regenerating mixture in NIP buffer. In right 3 panels, 2 mM GDP, GTP, or GTPgS was added. Cellular localization of the
substrates was determined by direct FITC fluorescence observation. Ran freshly loaded with GDP was labeled with PE (red) and used as a control. Scale bar,
20 mm.
(B) 5 mg indicated purified GST-tagged proteins were bound on glutathione beads and incubated in 2 mg/ml H1299 cell lysates for 2 hr at room temperature (RT),
followed by washes and immunoblotting.
(C) Control (Ctr) or importin-b1RNAi was transfected in H1299 cells for 24 hr, followed by ASPP-ARs-V5 or p53 transfection for another 48 hr. Cellular localizations
of transfected proteins and importin-b expression were determined. Scale bar, 20 mm.
See also Figure S1.To provide further evidence that ASPP-ARs can enter the
nucleus via an importin-independent pathway, importin-b1 was
knocked-down in H1299 cells before transfection with ASPP-
ARs or p53 (contains a NLS). While knockdown of importin-b11132 Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc.impaired p53’s nuclear accumulation, it had a minimal effect
on the nuclear accumulation of ASPP-ARs (Figure 1C). These
results suggest that ASPP-ARs can enter the nucleus indepen-
dently of importins.
ASPP-ARs Directly Bind RanGDP and Form an AR/
RanGDP/NTF2 Complex to Mediate Nuclear Entry
Since RanGDP continuously enters the nucleus via NTF2, we
tested whether ASPP-ARs could employ RanGDP to enter the
nucleus. ASPP-ARs-GST or GST was incubated with purified
RanGDP (freshly loaded GDP) in a GST pull-down assay. Direct
interaction between RanGDP and ASPP-ARs-GST, but not GST,
was observed (Figure 2A). The ARs-containing fragment (622-
757) mediated the observed interaction between iASPP and
RanGDP (Figure S2A).Previous studies imply that ARs bind their
partners in a manner where the ARs adopt a canonical tertiary
structure as observed in multiple crystal structures (Sedgwick
and Smerdon, 1999). By far-western dot blot assay, we
observed that only native ASPP-ARs-GST, and not urea-dena-
tured ASPP-ARs-GST, interacted with RanGDP (Figure 2B,
left). As a positive control, the membrane was incubated with
an anti-GST antibody that detects the presence of both native
and denatured ASPP-ARs-GST. Denaturation has minimal
impact on the signals detected (Figure 2B, right). Furthermore,
ASPP-ARs-GST failed to directly interact with FG-Nups (FxFG,
GLFG, SxFG, or PxFG) that are known to be involved in the
classical nuclear import pathway. NTF2’s interaction with
FxFG-containingNup153 acted as a positive control (Figure S2C)
(Morrison et al., 2003). These data suggest that ASPP-ARs bind
RanGDP directly in a tertiary structure-dependent manner, and
that the observed interaction with Nup153 in cell lysates may
be mediated by RanGDP/NTF2.
When NTF2 binds RanGDP, the resulting NTF2/RanGDP
complex enters the nucleus more efficiently than RanGDP alone
(Ribbeck et al., 1998). Although iASPP-ARs-GST was able to
bind RanGDP, it failed to interact directly with NTF2. However,
it did pull down NTF2 in the presence of RanGDP. In addition,
iASPP-ARs failed to pull down NTF2(E42K), a mutant defective
in RanGDP binding, in the presence of RanGDP. Interestingly,
iASPP-ARs-GST did not bind RanGTP under the same condi-
tions (Figure 2C).
In an in vitro nuclear import assay, incubation of FITC-labeled
iASPP-ARs-GST together with BSA detected nuclear iASPP-
ARs-GST in 89% of cells. Only 14% of the cells contained a
strong nuclear iASPP-ARs-GST signal (saturated FITC, red in
heat map, Figures 2D and S2D). However, in the presence of
RanGDP, 45% of cells manifested strong nuclear iASPP-
ARs-GST (Figure 2D and Figure S2D). Cells with nuclear
RanGDP were clearly associated with stronger nuclear iASPP-
ARs-GST signals (Figure 2D, arrowheads, enlarged panel).
Similar enhancement upon RanGDP addition was observed for
ASPP2-ARs-GST, but not NLS-GFP-GST, implying that
RanGDP nuclear import is specifically employed by ASPP-
ARs. Ran(Q69L)GTP, a dominant-negative mutant of Ran that
is locked in a GTP-bound form and defective in nuclear import,
reduced the percentage of strong nuclear iASPP-ARs-GST-
manifesting cells to <15%. Ran-GFP overexpression in H1299
cells induced stronger nuclear iASPP localization, while
Ran(Q69L)-GFP failed to do so (Figure 2E).
Incubation of iASPP-ARs-GST with RanGDP in the pre-
sence of NTF2 enhanced the nuclear iASPP-ARs-GST signal,
whereas NTF2(E42K) did not (Figure S2D). These results
demonstrate that the ASPP-ARs bind RanGDP directly, form-ing a protein complex with NTF2 via RanGDP that enables
their nuclear entry.
RanGDP Binds Hydrophobic 13th Residues of ARs and
Mediates Nuclear Import
The NPc (nucleophosmin core, a predominantly cytoplasmic
protein)-fused second AR of IkBa (NPc-IkBa-AR2) was pre-
viously shown to locate in the nucleus (Sachdev et al., 1998).
However, NPc-IkBa-AR2(AAA), a mutant with triple alanine sub-
stitutions on the 8th, 10th, and 13th residues of the AR, located in
the cytoplasm. Interestingly, NPc-IkBa-AR2 bound RanGDP
more strongly than NPc-IkBa-AR2(AAA) (Figure S3A). As NPc-Ik
Ba-AR2 contains only one AR, this provided an opportunity to
identify the specific AR residues that mediate RanGDP inter-
action. Previous studies have shown that ARs most commonly
interact with their binding partners via residues located on the
AR grooves, composed of the 3rd–15th residues in the AR
consensus sequence (Figure 3A, star line) (Sedgwick and Smer-
don, 1999). The start position of an AR is defined according to
common structural folds (Figure 3A). As RanGDP only binds
natively folded ASPP-ARs, the residues that maintain the AR’s
tertiary structure (Figure 3A, triangles; according to studies on
the artificial consensus AR) (Kohl et al., 2003) were not mutated.
Based on a crystal structure of IkBa’s ARs (PDB accession code:
1NFI), the 3rd, 5th, 13th, and 14th residues, which would not affect
AR structure but are located on the AR grooves, weremutated to
generate NPc-IkBa-AR2 (L114A, Q116A, I124A, and T125A),
respectively. Interestingly, only NPc-IkBa-AR2 (I124A, position
13) weakened RanGDP binding (Figure S3B). In the tertiary struc-
ture, the 13th AR residue (AR13) is located at the end of the first
a-helix (at the upper tip of the groove) and is exposed, extending
out of the AR (Figure 3A, red stars).
Within the UniProt Human Reviewed ARPs, the occurrence of
amino acids at the 13th positions of human ARs is biased toward
R, S, Q, and A (Figure S3B). Thus, AR13 of NPc-IkBa-AR2, I124,
was substituted individually with the ten most frequently occur-
ring amino acid residues (accounting for 79% of ARPs). The
resulting IkBa-AR2 mutants with hydrophobic AR13 (I124I,
I124L, I124F, and I124C) all bound RanGDP with high efficiency,
whereas mutants with more hydrophilic residues at AR13, K or R,
bound RanGDP with much lower efficiency (Figure 3B). Consis-
tent with RanGDP-binding affinity, strong RanGDP-binding NPc-
IkBa-AR2s (WT, I124L and I124F) were mainly observed in the
nucleus, whereas weaker mutants (NPc-IkBa-AR2[124R and
124K]) were predominantly cytoplasmic (Figure 3B).
ANKRD49 is predominantly cytoplasmic with four ARs, and
RanGDP binding is barely detectable. None of the four AR13s
of ANKRD49 (E, Y, K, and G) belongs to the highly hydrophobic
residues. They were thus substituted for the more hydrophobic I
and C, which occur at position 13 of the ARs of IkBa and iASPP,
respectively. Interestingly, a point substitution to replace the
existing Y or K to I or C, at AR13 of the second or third ARs,
achieved a small but detectable increase in RanGDP binding.
When two or more AR13 in consecutive ARs were substituted
for C (E-C-C-G or E-C-C-C), RanGDP binding was significantly
increased (Figure 3C), resulting in enhanced nuclear localization.
In addition, ANKRD49 mutants with hydrophobic AR13 in two
consecutive ARs were more active in binding RanGDP andCell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc. 1133
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more frequently localized in the nucleus than those with two
scattered ones (Figure 3C, E-C-K-C versus E-C-C-G).
Structural analysis revealed that a substantial hydrophobic
area exists in the C-terminal region of RanGDP (Figure 3D,
176-193, black dot circle), which is either disordered or adopts
a drastically different conformation in the RanGTP-bound form.
This area is located on the opposite side of the switch II area
(NTF2-binding sites, 65-83), supporting the notion that an
AR/RanGDP/NTF2 complex can be formed (Figure S3C). To
identify the key RanGDP residues that mediate the interaction
with hydrophobic AR13Hb, the eight structurally contiguous
hydrophobic residues (F176, V177, A181, L182, V187, V188,
A192, and L193) in this area were substituted for more hydro-
philic arginine residues, either singly or consecutively. While
RanGDP single mutants, Ran(V187R)GDP and Ran(V188R)
GDP, had minimal impact on binding to IkBa-AR2, RanGDP
double-mutant Ran(V187R/V188R)GDP showed a clear defect
in binding to IkBa-AR2 (Figure S3D). Similarly, the binding effi-
ciency between Ran(V187R/V188R)GDP and iASPP-ARs is
lower than the one betweenRanGDPand iASPP-ARs (Figure 3E).
The binding capacity and dissociation rates of Ran and
Ran(V187R/V188R) to GDP or GTP were then analyzed. Similar
binding affinities and dissociation rates for GDP or GTP
were detected for Ran and Ran(V187R/V188R) (Figures S3E
and S3F). Consistent with this, both Ran and Ran(V187R/
V188R) were imported into the nucleus in a semipermeable
nuclear import assay. Importantly, while RanGDP significantly
enhanced the nuclear import efficiency of iASPP-ARs-GST
and ASPP2-ARs-GST, the ability of the ARs binding-defect
Ran(V187R/V188R)GDP to enhance the nuclear import effi-
ciency of iASPP-ARs-GST and ASPP2-ARs-GST was impaired.
Under the same conditions, both RanGDP and Ran(V187R/
V188R)GDP had minimal impact on the nuclear import efficiency
of NLS-GFP-GST (Figures 3F and S3G and S3H).
Analysis of the computationally docked IkBa-RanGDP-NTF2
complex by HADDOCK suggested that such a ternary complex
is feasible, and could position the Ran C-terminal sequence to
interact with 2 adjacent ARs at a region centered on the AR13s
(Figure S3I) (Chen et al., 2011). These data demonstrate that
RanGDP’s C-terminal region is required to interact with the
AR13Hb, and that AR13Hbs at two consecutive AR stacks form a
better RanGDP binding surface than scattered AR13Hb. These
results also demonstrate that RanGDP needs to bind ARs to
enhance their nuclear import efficiency. RanGDP, but not
Ran(V187R/V188R)GDP, selectively enhances the nuclear
import efficiency of ARs whereas both RanGDP andFigure 2. ASPP-ARs Directly Bind RanGDP and Form an AR/RanGDP/
(A) 5 mg indicated purified GST-tagged proteins were bound on glutathione beads
BSA for 2 hr, followed by washes and immunoblotting.
(B) Twomicrogram of purified ASPP-ARs-GST was spotted on a nitrocellulose me
primary and secondary antibodies. Bottom: (denatured), the ASPP-ARs-GST we
(C) Indicated amounts of iASPP-ARs-GST, RanGDP, and NTF2 were mixed in NP4
glutathione beads, followed by immunoblotting.
(D) FITC (green) labeled ASPP-ARs-GST or NLS-GFP-GST was applied on semipe
(red) labeled BSA, RanGDP, or Ran(Q69L)GTP. Arrowheads/arrow: nucleus with
(E) iASPP-V5 was cotransfected with GFP, Ran-GFP, or Ran(Q69L)-GFP in H1299
bar, 20 mm.
See also Figure S2.Ran(V187R/V188R)GDP had minimal impact on the nuclear
import efficiency of NLS-GFP-GST. This further demonstrates
that the identified RaDAR pathway is distinct from the NLS/im-
portin-mediated nuclear import pathway.
The Most Common Familial Melanoma Mutation in
p16ink4a, Occurring at the Second AR13, Confers
RanGDP Binding and Nuclear Entry
The cyclin-dependent kinase inhibitor Ink4 family is among the
most frequently mutated ARPs in cancer cells, and p16ink4a
(p16) is frequently mutated in familial humanmelanomas. Among
the recorded 104 families with familial p16 point mutations, the
most frequently occurring event (19.2% frequency) is the M53I
mutation (GenoMEL) (Figure S4A) (Goldstein et al., 2006). The
AR13s of p16 are defined according to the crystal structure study
and, interestingly, M53 is the AR13 of p16’s second AR (Russo
et al., 1998). Another mutation at the AR13 of p16’s third AR,
p16(R87P), has also been detected in melanoma families
(1.0% frequency). Most tumor-derived p16 mutants are defec-
tive in CDK4 or CDK6 binding and the crystal structure of a
CDK6/p16 complex revealed that p16 residues R87 and M53
are located at the interface with CDK4/6 (Russo et al., 1998).
As expected, p16(R87P) exhibited a decrease in binding to
CDK4 and CDK6. However, p16(M53I) interacted with CDK4
and CDK6 as effectively as wild-type (WT) p16 in vitro and in
cell lysates (Figures 4A and 4B).
p16 inhibits cell-cycle entry by preventing cyclin D/CDK4 (or
CDK6) from phosphorylating RB. When p16 was induced in
U2OS cells (null of endogenous p16), it inhibited RB phosphory-
lation (Figure 4C) and suppressed cell growth (Figure 4D). Under
the same conditions, induced p16(M53I) and p16(R87P) failed to
inhibit RB phosphorylation and cell proliferation in U2OS. These
results demonstrate that although p16(M53I) binds CDK4/CDK6
as effectively as WT p16, it is functionally defective.
Nuclear cyclin D/CDKs are required to phosphorylate RB and
promote cell-cycle entry. Thus, the balance between nuclear
cyclin D/CDKs versus p16/CDKs is critical in controlling cell-
cycle progression. However, knowledge of how cyclin D,
CDK4, and CDK6 enter the nucleus is limited. p16 lacks an iden-
tifiable NLS and may enter the nucleus by diffusion, and is
detectable in both the cytoplasm and nucleus. However,
p16(M53I) is mainly nuclear in vivo in melanocytic lesions of
familial melanoma patients (Ghiorzo et al., 2004). Passive trans-
port alone cannot lead to nuclear accumulation (Kim and
Elbaum, 2013). In addition, most p16 is complexed with CDK4/
6 (resultant 40–66 kDa protein complex) under physiologicalNTF2 Complex to Mediate Nuclear Entry
and incubated in NP40 buffer containing 5 mg/ml purified RanGDP and 2mg/ml
mbrane and incubated with indicated proteins, followed by probing with shown
re incubated in 5 M Urea prior to spotting on the membrane.
0 buffer containing 2mg/ml BSA for 2 hr. iASPP-ARs-GST was pulled down by
rmeable H1299 cells (condition as Figure 1A) in the presence of 0.02 mg/ml PE
low/high levels of PE-Ran. Scale bar, 20 mm.
for 48 hr and its cellular localization determined using anti-V5 antibody. Scale
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conditions (McConnell et al., 1999). Key questions are how
p16(M53I) is translocated into the nucleus and why CDK4/6-
binding competent nuclear p16(M53I) loses its growth suppres-
sive property.
As M53 and R87 are the AR13 of p16’s ARs, M53I and R87P
mutations may increase p16’s RanGDP-binding affinity and
nuclear entry. An enhanced nuclear p16(M53I) pool could affect
CDK activity by altering CDK or cyclin D levels in the nucleus.
This theory was tested by transfecting p16(M53I) or p16(R87P)
into IGR39 melanoma cells, which do not express detectable
endogenous p16 (Lu et al., 2013). As expected, WT p16
was detected in both the cytoplasm and nucleus, whereas
p16(M53I) and p16(R87P) were mainly nuclear (Figure 4E).
RanGDP interacted with p16(M53I) and p16(R87P), but not p16
(Figure 4F). Consistent with the notion that RanGDP binding
contributes to the enhanced nuclear localization of p16(M53I)
and p16(R87P), this effect was largely abrogated by coexpres-
sion of p16(M53I) (or p16[R87P]) and Ran(Q69L), a dominant
negative Ran mutant (Figure S4B, p < 0.05).
It was observed that while most p16-expressing cells
expressed cytoplasmic cyclin D1 and CDK4/6, p16(M53I)-
expressing U2OS cells tended to express nuclear cyclin D1
and CDK4/6 (Figure 4G, S4C, p < 0.05). Notably, lower levels
of nuclear cyclin D1 and CDK4/6 were detected in cells express-
ing p16(R87P), a p16 mutant with reduced CDK4/6-binding
capability (Figure S4C). These results suggest that enhanced
nuclear accumulation of p16(M53I) via the RaDARpathway leads
to increased nuclear CDK4/6 (Figure S4D, middle). Increased
nuclear CDK4/6 may complex with cyclin D1 to retain it in the
nucleus and the efficiency of this step may also be affected by
an alteration in the affinity of p16(M53I) for CDK4/6. These obser-
vations explain how the M53I mutation may cause nuclear entry
and functional inactivation, and demonstrate the biological sig-
nificance of the RaDAR pathway.
RanGDP Binding to AR13Hb Defines a Nuclear Import
Pathway
The ability of RanGDP binding to AR13Hb to determine nuclear
import was tested using 17 representative ARPs. The 17 con-
structed ARDs, that have no putative cNLS, were tagged with
V5, FLAG, or GFP to generate fusion proteins larger than
30 kDa (Figure S5A top). GST-RanGDP was incubated with cell
lysates overexpressing the different ARs in GST pull-downFigure 3. RanGDP Binds Hydrophobic 13th Residue of AR and Mediate
(A) Left: schematic 3D structure of 3 consensus ARs (PDB: 1N0Q). Middle and ri
(B) NPc-IkBa-AR2 mutants (V5 tagged) were transfected into H1299 cells for 48
assay. In GST pull-down assay, 5 mg purified GST-RanGDP were bound on gluta
buffer) for 2 hr at RT, followed by washes and immunoblotting. Cellular locations o
Scale bar, 20 mm.(C) GST-RanGDP-binding capacities and cellular localization o
(D) The fold and surface properties of RanGDP (PDB: 1A2K, chain D) and Ra
hydrophobic surface enclosed within the black dotted lines is composed of resid
(E) Binding between the indicated GST-RanGDP mutants and iASPP-ARs was de
expressing iASPP-ARs-V5.
(F) FITC (green) labeled iASPP-ARs-GST was applied on semipermeable H1299 ce
RanGDP, or Ran(V187R/V188R)GDP. Top: the heat map of iASPP-ARs-GST si
according to the iASPP-ARs-GST heat map. Results were collected from two in
panel.
See also Figure S3.assays. GST-RanGDP interacted with some ARs, and the
binding intensities divided them into three groups. iASPP-ARs/
RanGDP binding was used to set a reference as 100%. Group
1 ARs (ASPP1, ASPP2, iASPP, IkBa, and TRPV4) bound
RanGDP strongly. Group 2 ARs (MYPT1, Tankyrase1, GABPb1,
and ANKRD49) had weak but detectable RanGDP binding.
Group 3 ARs (p16, p19, ANKFY1, AnkyrinR, AnkyrinB, AnkyrinG,
Notch1, and consensus ARs) had undetectable RanGDP binding
(Figure 5A and Figure S5A bottom). Surface plasmon resonance
(SPR)-binding assays showed that RanGDP-binding competent
group 1 ARPs, iASPP(625-828) and ASPP2(889-1128), specif-
ically bound GST-RanGDP with dissociation constants (Kd
values) of 151 nM and 69 nM, respectively (Figure 5B). In
contrast, the binding affinities between GST-RanGDP and
group 3 ARPs, 63 consensus ARs and AnkyrinR(402-827),
were undetectable under the same conditions (Figure S5B), con-
firming the direct interaction between RanGDP and group 1
ARPs. Interestingly, all group 1 ARs were predominantly nuclear,
whereas most of the group 2 and 3 ARs were predominantly
cytoplasmic (Figure 5C and S5C).
By examining the hydrophobicity of AR13 of the 17 ARDs, a
striking association emerged. RanGDP binding to identified
hydrophobic AR13 (I, L, F, or C) in consecutive ARs was only
found in group 1, but not in group 2 or 3, ARPs (Figure 5D).
These hydrophobic AR13 in nonconsecutive ARs were occa-
sionally found in group 2 and 3 ARs, consistent with those
observations made on ANKRD49 (Figure 3C), suggesting that
ARPs with hydrophobic AR13 in consecutive ARs show more
favorable interactions with RanGDP than scattered ones. As
ARs are arranged almost linearly, with only a 2–3 counter-
clockwise angle between neighboring repeats (Michaely et al.,
2002), the 3rd–15th residues of each AR form a continuous
groove that enables partner protein binding (Figure S5D, star
lines). AR13 is located on the upper tips of these grooves (red
stars), forming an area (circled by black dots, named ‘‘13th
patch’’) that is exposed and accessible for RanGDP binding.
Interestingly, it was found that group 1 ARPs exhibited an over-
all hydrophobic ‘‘13th patch,’’ while group 2 and 3 ARPs did not
(Figure S5E). In group 3, it is well known that cleaved C-termi-
nal Notch1 (Notch1-ICD) is imported into the nucleus via the
classical nuclear import pathway (Ranganathan et al., 2011).
It is consistent that Notch1-ARs are predominantly cyto-
plasmic, while Notch-ICD binds importin-a4 and is exclusivelys Nuclear Import
ght: consensus AR sequence. Position 13 is shown in red.
hr, and GST-RanGDP-binding capacities were determined by GST pull-down
thione beads and incubated in 2 mg/ml H1299 cell lysates (prepared in NP40
f NPc-IkBa-AR2mutants determined by anti-V5 antibody are shown at bottom.
f indicated ANKRD49 mutants were determined as for (B).
nGTP (PDB: 1QBK, chain C) created by Protein Workshop. The substantial
ues from the Ran C-terminal region.
termined as in (B) using purified GST-RanGDP mutants and H1299 cell lysate
lls (condition as Figure 1A) in the presence of 0.02 mg/ml PE (red) labeled BSA,
gnal. Bar graph shows the percentage of nuclei with varying FITC intensities
dividual experiments and shown as the mean; 100 cells were counted in each
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nuclear (Figure S5F). The hydrophobic ‘‘13th patch’’ may, there-
fore, provide access for RanGDP and define the RaDAR
pathway.
The Presence of AR13Hb in Two Consecutive ARs
Predicts ARP Cellular Localization
Among the 20,254 proteins of the UniProt Human Reviewed
Reference Proteins (UHRRP), 256 were identified as ARPs in a
homology search. Of the UHRRP proteins, 14,978 are assigned
a Cellular Component (C.C.) term by Gene Ontology (GO), and
151 are ARPs (Figure 6A). Interestingly, while 40% of UHRRP
are assigned a nuclear C.C. term, an increased proportion
(52%) of ARPs are assigned a nuclear C.C. term (p < 0.01).
Around 50% of >40 kDa ARPs and 58% of >100 kDa ARPs
were assigned a nuclear C.C. term, respectively (Figure 6A,
shaded area), which is significantly higher than those of non-
AR-containing proteins. This suggests a nuclear enrichment of
human ARPs that is not caused by passive diffusion of low mo-
lecular weight proteins through the NPC.
Nuclear enrichment of ARPs may be mediated by NLS. Using
the NLS-searching predictor NucPred (Brameier et al., 2007), we
divided the 151 ARPs with GO C.C. terms into three groups
according to NLS intensity (Figure S6A). When NLS-containing
proteins were excluded from further analysis, the percentage
of ARPs assigned a nuclear C.C. term was still higher than those
of UHRRP (Figure 6A, p < 0.01). This analysis suggests that ARPs
can enter the nucleus via an alternative import pathway to the
NLS/importin-dependent pathways.
The AR13 in individual ARs were identified using an unbiased
homology search (Table S1 listing the AR13 in 151 ARPs). Four-
teen of the 151 ARPs with GO C.C. terms contained I, L, F, or
C at the 13th positions of two consecutive ARs (denoted 23
ILFC). Twelve of these 23 ILFC ARPs (86%) were assigned a
nuclear C.C. term, while only 49% of the remaining 137 ARPs
were assigned a nuclear C.C. term (Figure S6B, p < 0.05).
When all hydrophobic residues (I, L, F, C, V, M, and A) were
considered, 30 of the 151 ARPs with a GO C.C. term (Figure 6B,
colorful pies) contained AR13Hb in two consecutive ARs (denoted
23 ILFCVMA, Table S2 listing the 30 23 ILFCVMA ARPs), and
16 of the 105 ARPswithout GOC.C. terms (blank pies) contained
23 ILFCVMA. Interestingly, 22 of the 30 23 ILFCVMA ARPs
(73%) had a nuclear C.C. term and only 57 of the remaining
121 ARPs (47%) had a nuclear C.C. term (Figure 6B, p = 0.01).
When all of the 46 23 ILFCVMA ARPs were analyzed, 34 had aFigure 4. The Most Common Familial MelanomaMutation in p16ink4a, O
(A) p16was prebound on protein G beads and incubatedwith NP40 buffer containi
and bound proteins were immunoblotted.
(B) U2OS cells with induced p16 were lysed in NP40 buffer and incubated with p
washed and bound proteins were immunoblotted.
(C) p16 was induced in U2OS cells in the presence of IPTG for 48 hr, and the RB
(D) p16-inducible U2OS cells were treated with IPTG on day 2 and cell numbers
(E) Cellular localization of transfected p16 mutants in p16 null IGR39 melanoma
exclusively nuclear p16 or indicated mutants (mean ± SD, n = 3, *p < 0.05).
(F) p16 or indicated mutants were in vitro translated and incubated with 5 mg GST
beads.
(G) Image shows the cellular location of transfected p16 (or p16[M53I]) in U2OS
(green), respectively. Scale bar, 20 mm.
See also Figure S4.nuclear term in either GO or HPA (The Human Protein Atlas),
seven were not yet annotated in either database, and only five
were assigned a nonnuclear term. Compared with the GO C.C.
terms assigned to UHRRP, the ‘‘nucleus’’ term was significantly
enriched in the 30 23 ILFCVMA ARPs (Figure 6C, left, p < 105),
while the ‘‘cytoplasm’’ term was enriched in the remaining 121
ARPswithout 23 ILFCMV (Figure S6C), suggesting the presence
of AR13Hb in two consecutive ARs (2x AR13Hb) may predict ARP
cellular localization.
Among the 30 ARPs with 23 ILFCVMA, ‘‘transcription factor
binding’’ was the enriched Molecular Function (M.F.) term in
GO and the enrichment was statistically significant against
GO-assigned UHRRP (Figure 6C, right, p < 105). The seven
proteins assigned this M.F. term were ANKRD42, iASPP,
ASPP2, and the NF-kB family members BCL3, IkBa, IkBd, and
NF-kB1. Further analysis of the 30 23 ILFCVMA ARPs revealed
that eight were NF-kB family members (Table S2, in yellow), 14
were previously shown to be regulators of NF-kB and/or p53
(in light yellow) and six were assigned an E3 ubiquitin-protein
ligase term in UniProt (in blue). No such M.F. term (transcription
factor binding) was enriched in the remaining 121 ARPs (Fig-
ure S6C, bottom).
In the set of 151 ARPs, the NLS motif tended to associate with
23 ILFCVMAmotif-free ARPs (Figure 6D, 23%versus 43%, 40%
versus 66%, p = 0.01). Notably, all seven ARPs containing both
motifs (as shown in Figure 6D) are large proteins (>120 kDa). For
large ARPs, both the RaDAR and importin-dependent pathways
may contribute to their nuclear localization, suggesting that
these two signal motifs generally tend to be mutually exclusive,
with either sufficient to mediate ARP nuclear entry.
The presence of AR13Hb was thus used to predict ARP nuclear
localization. Four different thresholds were used, based on
RanGDP-binding capability. The specificity and sensitivity of
these criteria to predict the nuclear localization of 151 GO C.C.
term-annotated ARPs was compared to the NLS score-based
prediction (Figure 6E; integrated prediction information is given
in Table S1). Around 73% of 23 ILFCVMA ARPs had a nuclear
C.C. term (specificity), accounting for 28% of the total 79 nuclear
ARPs (sensitivity). However, only 59% of NLS-containing ARPs
(NucPred score 0.9) had a nuclear C.C. term, and only 25%
of the total nuclear ARPs were covered. The same trend
was achieved when different thresholds were used. Similar
results were also obtained when compared to other NLS-based
nuclear localization prediction software including NLStradamus,ccurring at the Second AR13, Confers p16
ink4a Nuclear Accumulation
ng 2mg/ml BSA and 5 mg/ml purifiedCDK4/6-GST for 2 hr. Beadswere washed
rotein G beads and 2 mg corresponding CDK4/6 antibody for 2 hr. Beads were
phosphorylation pattern determined.
counted on days 3, 4, and 5 (mean ± SD, n = 3, *p < 0.05).
cells. Scale bar, 20 mM. Bar graph shows the percentage of cells expressing
-RanGDP in NP40 buffer, followed by GST pull-down assay using glutathione
cells. Endogenous CDK4, CDK6, and cyclin D1 (red) were costained with p16
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predictNLS, PSORT II, LOCtree, and BaCello (data not shown).
This analysis demonstrates that the presence of 23 AR13Hb is
more specific and sensitive than predictors based on the NLS
in predicting the nuclear localization of ARPs.
DISCUSSION
Protein function is dictated by cellular localization. Since the
identification of the first NLS in 1984, most nuclear import
pathways have been characterized as (centering on) employing
importin-cargo interaction-mediated nuclear import pathways.
However, these pathways cannot adequately explain how
nuclear entry is achieved for the entire proteome, as many of
the nuclear proteomic proteins do not have an identifiable
NLS. One of the major conceptual challenges is whether a
general nuclear import pathway exits that is parallel to the impor-
tin-cargo-mediated nuclear import pathway. Our results identify
the RaDAR pathway as one such pathway (Figure S6D). Strong
and specific binding is necessary for the transport receptor to
detect and capture its cargo in the cytoplasm and to maintain
a stable complex as it crosses the nuclear pores. Consistent
with this, the Kds between monopartite (SV40 NLS) or bipartite
(nucleoplasmin) NLS and the importin-a/b complex, measured
by SPR, is 35 nM and 48 nM, respectively (Catimel et al.,
2001). The Kd between M9 PY-NLS and transportin measured
by isothermal titration calorimetry (ITC) is 42 nM (Lee et al.,
2006). The Kd between RanGDP and NTF2 is 152 nM by ITC
(Chaillan-Huntington et al., 2000). In contrast to the cargo and
transport receptor interaction, the binding affinity between the
transport complex and FG-Nup is much weaker. A low binding
affinity between the transport complex and the NPC may enable
rapid attachment and detachment, as a high binding affinity
would imply slow off-rates (Stewart, 2007). The observed
binding affinities between group 1 ARPs and RanGDP (Kd of
69 and 151 nM) are well-suited for RanGDP to detect and
capture ARPs in the cytoplasm, providing strong supporting
evidence that the identified RaDAR complex fulfills the require-
ments of being a novel cargo and transport receptor complex
for nuclear import.
Our results also reveal differences between the RaDAR
pathway and the nuclear import mechanism reported previously
for CapG (Van Impe et al., 2008). First, the binding epitope
between the cargo and transport receptor is different. Although
CapG directly binds both NTF2 and Ran simultaneously, CapG
mainly binds NTF2 to achieve nuclear import while Ran plays a
supplementary role by enhancing their binding. CapG binds
NTF2 with a Kd of 6,300 nM. The presence of Ran enhances
the CapG/NTF2 binding (Kd = 3,800 nM). In contrast, ARPs
directly bind RanGDP and complex with NTF2 indirectly viaFigure 5. RanGDP Binding to AR13Hb Defines a Nuclear Import Pathwa
(A) Indicated ARs were transfected into H1299 cells and their binding to GST-R
(as Figure 3B).
(B) Purified biotinylated ASPP fragments were immobilized onto a sensor chip cou
were obtained by nonlinear regression assuming the Langmuir adsorption mode
proteins is shown.
(C) Cellular localizations of ARs from (A) were determined. Scale bar, 20 mm.
(D) Table lists the RanGDP binding and observed cellular localizations of 17 ARD
See also Figure S5.Ran. Moreover, there is a striking difference in the binding affinity
between the cargo and transport receptor between CapG/NTF2/
Ran versus RaDAR. In the RaDAR pathway, the cargo/receptor
binding affinities are 25-55-fold stronger than those of CapG/
NTF2/Ran. CapG directly binds Nup62 during NPC crossing,
while binding of ARPs andNup62was undetectable in this study.
It is possible that the previously reported CapG/NTF2/Ran
nuclear import pathway may be specific to CapG, whereas the
identified RaDAR pathway represents a more general nuclear
import pathway.
The RaDAR pathway may explain why some ARPs are located
in the nucleus without a detectable NLS. One such example is
Tankyrase1. Tankyrase1 belongs to a nuclear protein family,
poly(ADP-ribose) polymerase (PARP), and regulates telomere
length. While other PARP family members such as PARP1
contain an obvious NLS (Rouleau et al., 2010), Tankyrase1 lacks
one and it is unknown how it gains nuclear entry. One possible
mechanism is that it piggybacks on NLS-containing proteins
(Smith and de Lange, 1999). Alternatively, since Tankyrase1
can bind RanGDP it may use the RaDAR pathway.
The identified RaDAR pathway may provide a molecular
explanation for the behavior of numerous ARP mutations in
human disease, as demonstrated by the most common familial
melanoma founder mutation, p16(M53I). M53I mutation confers
p16 RanGDP binding and nuclear enrichment. Nuclear
p16(M53I)-expressing cells often coexpress nuclear Cyclin D1
and nuclear CDK4/6. Consistent with the fact that p16(R87P)
does not interact with CDK4/6 as efficiently as p16(M53I),
nuclear p16(R87P)-expressing cells contain less nuclear Cyclin
D1 or nuclear CDK4/6 comparing to p16(M53I)-expressing
cells. Therefore, enhanced nuclear p16(M53I), as a result of its
uptake via the RaDAR pathway, could lead to increased nuclear
CDK4/6 that may retain cyclin D1 in the nucleus and enhance
nuclear cyclin D1/CDK’s kinase activity to phosphorylate RB
and promote cell-cycle entry. Hence, the RaDAR pathway
may not only determine the cellular localization of ARPs, but
also influence the cellular localization of ARP-interacting
proteins.
Finally, unlike the PY-NLS, which is a linear disordered amino
acid sequence often located on a protein’s surface (Lee et al.,
2006), the AR is a highly structured and well-characterized
protein motif. The AR code for RaDAR formation is tertiary struc-
ture-dependent, and defines an interaction surface (13th patch)
for RanGDP binding. This may be part of the reason why the
presence of a 23 AR13Hb code for RanGDP binding enabled us
to predict nuclear ARPs with high accuracy. Strikingly, detailed
analysis of the 30 ARPs that contain 23 AR13Hb revealed three
functional clusters. Cluster 1 contains known NF-kB family
members, whereas cluster 2 consists of regulators of NF-kBy
anGDP determined in a GST pull-down assay using transfected cell lysates
pled with streptavidin, followed by SPR assay. Values of Kd with GST-RanGDP
l. RU, response units. Coomassie blue staining of approximate 1 mg purified
s derived from (A) and (C). AR13 was defined by UniProt.
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and/or p53. The two clusters together account for >70% of the
identified 23x AR13Hb ARPs. The ASPP family proteins were
originally identified as binding partners of p53 and p65/RelA.
Studies over the past 10 years have established ASPPs as
important regulators of p53, p63, and p73 (Bergamaschi et al.,
2004). However, much less is known about the biological impor-
tance of the ASPP/p65 interaction. The functional interplay
between NF-kB and p53 is emerging. Thus, the identification
of the RaDAR pathway as a common pathway regulating the
nuclear entry of NF-kB family members/regulators and ASPP
reveals a new dimension to the crosstalk between NF-kB and
p53. Finally, cluster 3 ARPs are assigned an ‘‘E3 ubiquitin-pro-
tein ligase’’ term in UniProt. Although the significance of cluster
3 is unknown, it is possible that they may also play a role in regu-
lating NF-kB/p53 signaling, since the stabilities of IkB and p53
are largely regulated by ubiquitin-mediated protein degradation
(Brooks and Gu, 2006; Deng et al., 2000). Interestingly, four of
them (MIB1, MIB2, ASB9, and FEM1A) are reported to regulate
NF-kB’s activities (Table S2). Regardless, the remarkably high
frequency of 23 AR13Hb ARPs in regulating NF-kB/p53 signaling
argues for the importance of the identified RaDAR pathway in
diseases such as cancer and inflammation, in which the NF-
kB/p53 pathways are deregulated.
Over 250 ARPs are predicted in the human proteome with
diverse biological functions, and ARs are one of the most
common repeat motifs that mediate protein-protein interactions.
The identification of an AR code for RanGDP binding provides a
proof of principle that binding specificities of ARs to their inter-
acting proteins may be predetermined by their amino acid
sequences. This knowledge will undoubtedly extend our under-
standing of howARPs and their interacting proteins function, and
will also inform the protein engineering of specific recognition
motifs with particular cellular localizations in order to benefit
human health.
EXPERIMENTAL PROCEDURES
Computational Protein Sequence Analysis
A multiple protein sequence alignment of ARs was obtained from the Pfam
database. Profiles of the alignment were generated using HMMer2. Iterative
similarity searches were performed with HMMer2 against the UHRRP data-
base. GO term searches were performed in September, 2013. See Extended
Experimental Procedures.
Immunoprecipitation
Cells were lysed in NP40 buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1%
NP40) with protease inhibitor cocktail. After Sonication and spinning, super-
natant was adjusted to a final concentration of 2 mg/ml total protein using
NP40 buffer. 400 ml cell lysate was incubated with 20 ml protein G beads andFigure 6. The Presence of 23 AR13Hb Predicts ARP Nuclear Localizatio
(A) Pie charts show the percentage of UHRRP and ARPs that are assigned with nu
NLS were excluded. p value shows the difference between UHRRP and ARPs.
(B) 151 ARPs with GO C.C. terms and 105 ARPs without GO C.C. terms were divid
analysis as (A).
(C) The 151 identified ARPswith a 23 ILFCVMAmotif were subjected to C.C. andM
Background: 20254 UHRRP. 18790 proteins from UHRRP were annotated in the
(D) Bar graph shows the occurrence frequency of NLSs in ARPs with/without a 2
(E) The specificity and sensitivity of nuclear localization predictions on 151 ARPs a
See also Figure S6, Table S1, S2.2 mg corresponding primary antibody for 2 hr at room temperature (RT). Beads
were washed four times with NP40 buffer, boiled for 5 min in SDS loading
buffer, and used for immunoblotting.
GST Pull-Down
Glutathione beads preincubated with 5 mg purified GST-tagged proteins were
incubated in 400 ml NP40 buffer containing 2 mg/ml prepared cell lysate
(or NP40 buffer containing 5 mg/ml purified proteins and 2 mg/ml BSA or
NP40 buffer containing 10 ml in vitro-translated protein lysate) for 2 hr at RT,
followed by washes and immunoblotting.
Ran Nucleotides Loading/Dissociation
A solution of Ran at 20 uM concentration was dialyzed against loading buffer
(10 mM HEPES [pH 7.3], 160 mM potassium acetate, 5 mM magnesium
acetate, 1 mM DTT) at 4C overnight (O/N). Dialyzed Ran proteins were incu-
bated with 1 mM of the respective nucleotides in the presence of 15 mMEDTA
for 60 min at RT. Magnesium acetate was added to a final concentration of
30 mM.
Protein Fluorescent Labeling and In Vitro Nuclear Import Assay
Ran was loaded with nucleotides immediately prior to experiments. Purified
proteins were labeled with FITC or phycoerythrin (PE) using commercially
available kits. Digitonin-treated semipermeable cells were incubated in
nuclear transport buffer (NIB: 20 mM HEPES [pH 7.3], 110 mM potassium
acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 2 mM DTT,
0.5 mM EGTA, and protease inhibitors) with 0.02 mg/ml FITC-labeled sub-
strates, 10 mg/ml H1299 cytosol, and an energy-regenerating mixture
(1 mM ATP, 0.1 mM GTP, 5 mM creatine phosphate, and 20 U/ml creatine
phosphokinase) at RT for 40 min. Cellular localization of the substrate was
determined by direct FITC or PE fluorescence observation with a confocal
microscope.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.05.006.
AUTHOR CONTRIBUTIONS
X.L. oversaw the project. M.L. and X.L. conceived and designed the study and
wrote the manuscript. M.L., J.Z., S.C., L.S.P. and D.T.S. performed the exper-
iments and J.E., C.P.P. and C.J.S. supervised part of the project. All authors
interpreted data and edited the manuscript.
ACKNOWLEDGMENTS
This work was funded by the Ludwig Institute for Cancer Research Ltd. We
thank Andrew Wilde, Katrien Van Impe, Paul Clarke, Svitlana Korolchuk,
Ming Yang, Vann Bennett, Matthew Cockman, and Mark Hannink for the
generous gift of plasmids or proteins. We thank Yvonne Jones for generous
access to facilities for protein production. We thank Claire Beveridge and Kim-
berley Bryon-Dodd for critical reading of the manuscript.n
clear C.C. terms in GO. Proteins with <40 or 100 kDa (shaded area) or a putative
ed into two groups according to the occurrence of a 23 ILFCVMA, followed by
.F. enrichment analysis and the significant enrichments were shown (colored).
GO.
3 ILFCVMA motif.
ccording to the occurrence of AR13Hb (red line) or NLS (green line, by NucPred).
Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc. 1143
Received: September 10, 2013
Revised: January 22, 2014
Accepted: March 13, 2014
Published: May 22, 2014
REFERENCES
Adams, R.L., andWente, S.R. (2013). Uncovering nuclear pore complexity with
innovation. Cell 152, 1218–1221.
Agrawal, N., Frederick, M.J., Pickering, C.R., Bettegowda, C., Chang, K., Li,
R.J., Fakhry, C., Xie, T.X., Zhang, J., Wang, J., et al. (2011). Exome sequencing
of head and neck squamous cell carcinoma reveals inactivating mutations in
NOTCH1. Science 333, 1154–1157.
Aylon, Y., Ofir-Rosenfeld, Y., Yabuta, N., Lapi, E., Nojima, H., Lu, X., and Oren,
M. (2010). The Lats2 tumor suppressor augments p53-mediated apoptosis by
promoting the nuclear proapoptotic function of ASPP1. Genes Dev. 24, 2420–
2429.
Bennett, V., and Baines, A.J. (2001). Spectrin and ankyrin-based pathways:
metazoan inventions for integrating cells into tissues. Physiol. Rev. 81,
1353–1392.
Bergamaschi, D., Samuels, Y., Jin, B., Duraisingham, S., Crook, T., and Lu, X.
(2004). ASPP1 and ASPP2: common activators of p53 family members. Mol.
Cell. Biol. 24, 1341–1350.
Brameier, M., Krings, A., and MacCallum, R.M. (2007). NucPred—predicting
nuclear localization of proteins. Bioinformatics 23, 1159–1160.
Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol.
Cell 21, 307–315.
Catimel, B., Teh, T., Fontes, M.R., Jennings, I.G., Jans, D.A., Howlett, G.J.,
Nice, E.C., and Kobe, B. (2001). Biophysical characterization of interactions
involving importin-alpha during nuclear import. J. Biol. Chem. 276, 34189–
34198.
Chaillan-Huntington, C., Braslavsky, C.V., Kuhlmann, J., and Stewart, M.
(2000). Dissecting the interactions between NTF2, RanGDP, and the nucleo-
porin XFXFG repeats. J. Biol. Chem. 275, 5874–5879.
Chen, S., Bubeck, D., MacDonald, B.T., Liang, W.X., Mao, J.H., Malinauskas,
T., Llorca, O., Aricescu, A.R., Siebold, C., He, X., and Jones, E.Y. (2011). Struc-
tural and functional studies of LRP6 ectodomain reveal a platform for Wnt
signaling. Dev. Cell 21, 848–861.
Chook, Y.M., and Su¨el, K.E. (2011). Nuclear import by karyopherin-bs: recog-
nition and inhibition. Biochim. Biophys. Acta 1813, 1593–1606.
Cook, A., Bono, F., Jinek, M., and Conti, E. (2007). Structural biology of nucle-
ocytoplasmic transport. Annu. Rev. Biochem. 76, 647–671.
Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C.,
Pickart, C., and Chen, Z.J. (2000). Activation of the IkappaB kinase complex
by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a
unique polyubiquitin chain. Cell 103, 351–361.
Dreier, B., Honegger, A., Hess, C., Nagy-Davidescu, G., Mittl, P.R., Gru¨tter,
M.G., Belousova, N., Mikheeva, G., Krasnykh, V., and Plu¨ckthun, A. (2013).
Development of a generic adenovirus delivery system based on structure-
guided design of bispecific trimeric DARPin adapters. Proc. Natl. Acad. Sci.
USA 110, E869–E877.
Eber, S.W., Gonzalez, J.M., Lux, M.L., Scarpa, A.L., Tse, W.T., Dornwell, M.,
Herbers, J., Kugler, W., Ozcan, R., Pekrun, A., et al. (1996). Ankyrin-1 muta-
tions are a major cause of dominant and recessive hereditary spherocytosis.
Nat. Genet. 13, 214–218.
Fagotto, F., Glu¨ck, U., and Gumbiner, B.M. (1998). Nuclear localization signal-
independent and importin/karyopherin-independent nuclear import of beta-
catenin. Curr. Biol. 8, 181–190.
Ghiorzo, P., Villaggio, B., Sementa, A.R., Hansson, J., Platz, A., Nicolo´, G.,
Spina, B., Canepa, M., Palmer, J.M., Hayward, N.K., and Bianchi-Scarra`, G.
(2004). Expression and localization of mutant p16 proteins in melanocytic
lesions from familial melanoma patients. Hum. Pathol. 35, 25–33.1144 Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc.Goldstein, A.M., Chan, M., Harland, M., Gillanders, E.M., Hayward, N.K., Avril,
M.F., Azizi, E., Bianchi-Scarra, G., Bishop, D.T., Bressac-de Paillerets, B.,
et al.; MelanomaGenetics Consortium (GenoMEL) (2006). High-riskmelanoma
susceptibility genes and pancreatic cancer, neural system tumors, and uveal
melanoma across GenoMEL. Cancer Res. 66, 9818–9828.
Go¨rlich, D., and Kutay, U. (1999). Transport between the cell nucleus and the
cytoplasm. Annu. Rev. Cell Dev. Biol. 15, 607–660.
Kim, S., and Elbaum,M. (2013). A simple kinetic model with explicit predictions
for nuclear transport. Biophys. J. 105, 565–569.
Kohl, A., Binz, H.K., Forrer, P., Stumpp, M.T., Plu¨ckthun, A., and Gru¨tter, M.G.
(2003). Designed to be stable: crystal structure of a consensus ankyrin repeat
protein. Proc. Natl. Acad. Sci. USA 100, 1700–1705.
Kose, S., Furuta, M., and Imamoto, N. (2012). Hikeshi, a nuclear import carrier
for Hsp70s, protects cells from heat shock-induced nuclear damage. Cell 149,
578–589.
Kutay, U., Bischoff, F.R., Kostka, S., Kraft, R., and Go¨rlich, D. (1997). Export of
importin alpha from the nucleus is mediated by a specific nuclear transport
factor. Cell 90, 1061–1071.
Lee, B.J., Cansizoglu, A.E., Su¨el, K.E., Louis, T.H., Zhang, Z., and Chook, Y.M.
(2006). Rules for nuclear localization sequence recognition by karyopherin
beta 2. Cell 126, 543–558.
Lu, M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I.,
Sullivan, A., Brown, N.R., Endicott, J., et al. (2013). Restoring p53 function in
human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphory-
lated nuclear iASPP. Cancer Cell 23, 618–633.
McConnell, B.B., Gregory, F.J., Stott, F.J., Hara, E., and Peters, G. (1999).
Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated
kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell.
Biol. 19, 1981–1989.
Melchior, F., Paschal, B., Evans, J., and Gerace, L. (1993). Inhibition of nuclear
protein import by nonhydrolyzable analogues of GTP and identification of the
small GTPase Ran/TC4 as an essential transport factor. J. Cell Biol. 123, 1649–
1659.
Michaely, P., Tomchick, D.R., Machius, M., and Anderson, R.G. (2002). Crystal
structure of a 12 ANK repeat stack from human ankyrinR. EMBO J. 21, 6387–
6396.
Mohler, P.J., Schott, J.J., Gramolini, A.O., Dilly, K.W., Guatimosim, S., duBell,
W.H., Song, L.S., Haurogne´, K., Kyndt, F., Ali, M.E., et al. (2003). Ankyrin-B
mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac
death. Nature 421, 634–639.
Mohr, D., Frey, S., Fischer, T., Gu¨ttler, T., and Go¨rlich, D. (2009). Characterisa-
tion of the passive permeability barrier of nuclear pore complexes. EMBO J.
28, 2541–2553.
Morrison, J., Yang, J.C., Stewart, M., and Neuhaus, D. (2003). Solution NMR
study of the interaction between NTF2 and nucleoporin FxFG repeats.
J. Mol. Biol. 333, 587–603.
Notari, M., Hu, Y., Koch, S., Lu, M., Ratnayaka, I., Zhong, S., Baer, C., Pagotto,
A., Goldin, R., Salter, V., et al. (2011). Inhibitor of apoptosis-stimulating protein
of p53 (iASPP) prevents senescence and is required for epithelial stratification.
Proc. Natl. Acad. Sci. USA 108, 16645–16650.
Ranganathan, P., Weaver, K.L., and Capobianco, A.J. (2011). Notch signalling
in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer
11, 338–351.
Ribbeck, K., Lipowsky, G., Kent, H.M., Stewart, M., and Go¨rlich, D. (1998).
NTF2 mediates nuclear import of Ran. EMBO J. 17, 6587–6598.
Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H., and Poirier, G.G.
(2010). PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293–301.
Russo, A.A., Tong, L., Lee, J.O., Jeffrey, P.D., and Pavletich, N.P. (1998).
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the
tumour suppressor p16INK4a. Nature 395, 237–243.
Sachdev, S., Hoffmann, A., and Hannink, M. (1998). Nuclear localization of
IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha
ankyrin repeats define a novel class of cis-acting nuclear import sequences.
Mol. Cell. Biol. 18, 2524–2534.
Samuels-Lev, Y., O’Connor, D.J., Bergamaschi, D., Trigiante, G., Hsieh, J.K.,
Zhong, S., Campargue, I., Naumovski, L., Crook, T., and Lu, X. (2001). ASPP
proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8,
781–794.
Sedgwick, S.G., and Smerdon, S.J. (1999). The ankyrin repeat: a diversity of
interactions on a common structural framework. Trends Biochem. Sci. 24,
311–316.
Slee, E.A., Gillotin, S., Bergamaschi, D., Royer, C., Llanos, S., Ali, S., Jin, B.,
Trigiante, G., and Lu, X. (2004). The N-terminus of a novel isoform of human
iASPP is required for its cytoplasmic localization. Oncogene 23, 9007–9016.
Smith, S., and de Lange, T. (1999). Cell cycle dependent localization of the
telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes.
J. Cell Sci. 112, 3649–3656.
Sottocornola, R., Royer, C., Vives, V., Tordella, L., Zhong, S., Wang, Y.,
Ratnayaka, I., Shipman, M., Cheung, A., Gaston-Massuet, C., et al. (2010).
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progen-
itors during CNS development. Dev. Cell 19, 126–137.Stewart, M. (2007). Molecular mechanism of the nuclear protein import cycle.
Nat. Rev. Mol. Cell Biol. 8, 195–208.
Van Impe, K., Hubert, T., De Corte, V., Vanloo, B., Boucherie, C., Vandekerck-
hove, J., and Gettemans, J. (2008). A new role for nuclear transport factor 2
and Ran: nuclear import of CapG. Traffic 9, 695–707.
Vigneron, A.M., Ludwig, R.L., and Vousden, K.H. (2010). Cytoplasmic ASPP1
inhibits apoptosis through the control of YAP. Genes Dev. 24, 2430–2439.
Vives, V., Su, J., Zhong, S., Ratnayaka, I., Slee, E., Goldin, R., and Lu, X. (2006).
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to
suppress tumor growth. Genes Dev. 20, 1262–1267.
Wang, Y., Godin-Heymann, N., Dan Wang, X., Bergamaschi, D., Llanos, S.,
and Lu, X. (2013). ASPP1 and ASPP2 bind active RAS, potentiate RAS signal-
ling and enhance p53 activity in cancer cells. Cell Death Differ. 20, 525–534.
Weis, K. (2003). Regulating access to the genome: nucleocytoplasmic trans-
port throughout the cell cycle. Cell 112, 441–451.
Yang, J.P., Hori, M., Sanda, T., and Okamoto, T. (1999). Identification of a
novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J. Biol.
Chem. 274, 15662–15670.Cell 157, 1130–1145, May 22, 2014 ª2014 Elsevier Inc. 1145
